Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. AnorMED is focused on the discovery and development of new drugs for the treatment of a variety of diseases including
cancer, HIV and haematology. Its core strengths involve the application of chemistry, biochemistry and biology in order
to generate small molecules with therapeutic potential.
AnorMED was incorporated on 5th January 1996 by a team of seven scientists led by Dr Michael Abrams and Dr
Geoffrey Henson, both of whom worked together from 1985 as integral members of the biomedical research group of
Johnson Matthey (JM). This group was dedicated to the discovery and preclinical development of metal-based
pharmaceuticals. In 1995, JM decided to focus its pharmaceutical related business on core activities involving the
development and production of active pharmaceutical ingredients. This decision provided AnorMED's research team,
led by Abrams, with the opportunity to establish and lead an independent entity focused solely on the expansion of the
drug discovery and development activities formerly undertaken by the biomedical research group of JM. AnorMED
commenced operations on 1st April 1996.